HHS Nominee Azar And The Taint Of Industry
Executive Summary
During the first step of the confirmation process, HHS Secretary nominee Alex Azar did a good job of framing his industry background as useful experience for tackling drug prices. But wouldn’t it be nice if everyone agreed that 10 years as Lilly was something to be proud of?
You may also be interested in...
Lowering Insulin Costs: Sanofi Seeks HHS Support For Expanding Assistance To Medicare Patients
HHS endorsement of company-sponsored discount programs for cash-paying customers with Medicare would be preferable to lowering list pricing.
Diagnostics 2018: Steady Progress And The Big Get Bigger
If the beginning of 2017 was marked by doubts around whether and how the FDA would act with respect to complex diagnostics, we enter 2018 feeling that slow-moving vessel may finally be turning.
List Price Increase 'Incentives' Must Be Reversed, HHS Nominee Azar Says
Senate Finance Committee Democrats grill HHS Secretary nominee Alex Azar about his ability to foster solutions to high drug pricing given his industry background, as well as his support for alternative financing in Medicaid.